Rosiñol Laura, Cibeira M Teresa, Montoto Silvia, Rozman María, Esteve Jordi, Filella Xavier, Bladé Joan
Hematology Department, Institute of Hematology and Oncolog, Institut d'Investigacions Biomédiques Agustí Pi i Sunyer, Hospital Clinic, University of Barcelona, Spain.
Mayo Clin Proc. 2007 Apr;82(4):428-34. doi: 10.4065/82.4.428.
To investigate the predictors of monoclonal gammopathy of undetermined significance (MGUS) by considering not only the initial features but also the pattern of evolution of the M protein during the first years after diagnosis.
This study consisted of 359 patients diagnosed as having MGUS at a single institution. Patients who showed a definite and progressive increase in their M protein size according to serum electrophoresis during the first 3 years of follow-up were considered to have evolving MGUS, whereas all others were considered to have nonevolving MGUS.
Of the 359 patients, 330 had nonevolving MGUS, whereas 29 fulfilled the criteria for evolving MGUS. Overall, 32 patients developed malignant transformation. The progression rates at 10 and 20 years of follow-up for the evolving and the nonevolving types were 55% vs 10% and 80% vs 13%, respectively. Multivariate analysis revealed that the features significantly associated with a higher risk of progression were evolving MGUS (relative risk [RR], 12.14; P<.001), IgA MGUS (RR, 2.93; P=.006), and M protein concentration (RR, 2.18; P=.04).
The evolutionary pattern of serum M protein (progressive increasing vs stable) during the first years of follow-up is the most important risk factor for disease progression in patients with MGUS.
通过不仅考虑初始特征,还考虑诊断后最初几年中M蛋白的演变模式,来研究意义未明的单克隆丙种球蛋白病(MGUS)的预测因素。
本研究纳入了在单一机构被诊断为MGUS的359例患者。根据血清电泳结果,在随访的前3年中M蛋白大小出现明确且进行性增加的患者被视为有进展性MGUS,而其他所有患者被视为无进展性MGUS。
在这359例患者中,330例有无进展性MGUS,而29例符合进展性MGUS的标准。总体而言,32例患者发生了恶性转化。进展性和无进展性类型在随访10年和20年时的进展率分别为55%对10%和80%对13%。多因素分析显示,与较高进展风险显著相关的特征是进展性MGUS(相对风险[RR],12.14;P<0.001)、IgA MGUS(RR,2.93;P = 0.006)和M蛋白浓度(RR,2.18;P = 0.04)。
随访最初几年中血清M蛋白的演变模式(进行性增加与稳定)是MGUS患者疾病进展的最重要危险因素。